Literature DB >> 9624165

Cryptic Rac-binding and p21(Cdc42Hs/Rac)-activated kinase phosphorylation sites of NADPH oxidase component p67(phox).

S Ahmed1, E Prigmore, S Govind, C Veryard, R Kozma, F B Wientjes, A W Segal, L Lim.   

Abstract

Rac1 is a member of the Rho family of small molecular mass GTPases that act as molecular switches to control actin-based cell morphology as well as cell growth and differentiation. Rac1 and Rac2 are specifically required for superoxide formation by components of the NADPH oxidase. In binding assays, Rac1 interacts directly with p67(phox), but not with the other oxidase components: cytochrome b, p40(phox), or p47(phox) (Prigmore, E., Ahmed, S., Best, A., Kozma, R. , Manser, E., Segal, A. W., and Lim, L. (1995) J. Biol. Chem. 270, 10717-10722). Here, the Rac1/2 interaction with p67(phox) has been characterized further. Rac1 and Rac2 can bind to p67(phox) amino acid residues 170-199, and the N terminus (amino acids 1-192) of p67(phox) can be used as a specific inhibitor of Rac signaling. Deletion of p67(phox) C-terminal sequences (amino acids 193-526), the C-terminal SH3 domain (amino acids 470-526), or the polyproline-rich motif (amino acids 226-236) stimulates Rac1 binding by approximately 8-fold. p21(Cdc42Hs/Rac)-activated kinase (PAK) phosphorylates p67(phox) amino acid residues adjacent to the Rac1/2-binding site, and this phosphorylation is stimulated by deletion of the C-terminal SH3 domain or the polyproline-rich motif. These data suggest a role for cryptic Rac-binding and PAK phosphorylation sites of p67(phox) in control of the NADPH oxidase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624165     DOI: 10.1074/jbc.273.25.15693

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

Review 1.  Chronic granulomatous disease.

Authors:  D Goldblatt; A J Thrasher
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

Review 2.  Versatile TPR domains accommodate different modes of target protein recognition and function.

Authors:  Rudi Kenneth Allan; Thomas Ratajczak
Journal:  Cell Stress Chaperones       Date:  2010-12-09       Impact factor: 3.667

Review 3.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

4.  p21-activated kinase (Pak) regulates NADPH oxidase activation in human neutrophils.

Authors:  Kendra D Martyn; Moon-Ju Kim; Mark T Quinn; Mary C Dinauer; Ulla G Knaus
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

5.  The major phosphorylation site of the NADPH oxidase component p67phox is Thr233.

Authors:  L V Forbes; O Truong; F B Wientjes; S J Moss; A W Segal
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

6.  Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammation.

Authors:  Emily E Bosco; Sachin Kumar; Filippo Marchioni; Jacek Biesiada; Miroslaw Kordos; Kathleen Szczur; Jarek Meller; William Seibel; Ariel Mizrahi; Edgar Pick; Marie-Dominique Filippi; Yi Zheng
Journal:  Chem Biol       Date:  2012-02-24

Review 7.  P21-activated kinase in inflammatory and cardiovascular disease.

Authors:  Domenico M Taglieri; Masuko Ushio-Fukai; Michelle M Monasky
Journal:  Cell Signal       Date:  2014-05-02       Impact factor: 4.315

8.  p21-activated kinase signaling regulates oxidant-dependent NF-kappa B activation by flow.

Authors:  A Wayne Orr; Cornelia Hahn; Brett R Blackman; Martin Alexander Schwartz
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

Review 9.  Emerging evidence for the importance of phosphorylation in the regulation of NADPH oxidases.

Authors:  Gary M Bokoch; Becky Diebold; Jun-Sub Kim; Davide Gianni
Journal:  Antioxid Redox Signal       Date:  2009-10       Impact factor: 8.401

Review 10.  PAK signaling in oncogenesis.

Authors:  P R Molli; D Q Li; B W Murray; S K Rayala; R Kumar
Journal:  Oncogene       Date:  2009-05-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.